Insider Selling: Immunome (NASDAQ:IMNM) Insider Sells $1,091,750.00 in Stock

Posted by Stanley Muller on Jun 29th, 2026

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $19.85, for a total transaction of $1,091,750.00. Following the transaction, the insider owned 15,805 shares in the company, valued at approximately $313,729.25. The trade was a 77.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Price Performance

Shares of NASDAQ IMNM traded up $1.08 during mid-day trading on Monday, hitting $21.04. The company had a trading volume of 1,597,353 shares, compared to its average volume of 1,425,521. The business’s 50-day simple moving average is $21.13 and its 200-day simple moving average is $21.72. Immunome, Inc. has a 12 month low of $7.96 and a 12 month high of $27.65. The firm has a market cap of $2.38 billion, a P/E ratio of -8.84 and a beta of 2.04.

Immunome (NASDAQ:IMNM – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, sell-side analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on IMNM shares. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Barclays began coverage on Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price for the company. Truist Financial lifted their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average target price of $33.17.

Get Our Latest Research Report on Immunome

Institutional Investors Weigh In On Immunome

A number of institutional investors have recently added to or reduced their stakes in the stock. Creative Planning grew its stake in shares of Immunome by 4.0% in the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after purchasing an additional 710 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after buying an additional 935 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Immunome by 1.8% during the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after buying an additional 1,167 shares during the period. Assetmark Inc. lifted its position in shares of Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after buying an additional 1,442 shares during the period. Finally, Virtus Investment Advisers LLC boosted its stake in Immunome by 16.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after buying an additional 1,970 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

About Immunome

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.